Physician profile
Vidhya Sabapathy
NPI 1588058879
$3,650.14
in general payments reported to CMS, 2019-2025
22 companies · $950 in 2025
The $950 reported for 2025 was more than what 78% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.98 · 2020: $28.45 · 2021: $957 · 2022: $427 · 2023: $142 · 2024: $1,094 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,106 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,105.55 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $614.08 | 2021-2025 | Cabenuva, Dovato |
| Paratek Pharmaceuticals, INC. | $570.59 | 2021-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $508.09 | 2020-2025 | Pifeltro, Zerbaxa, Dificid |
| Insmed, INC. | $404.47 | 2021-2025 | Arikayce, Brinsupri |
| Gilead Sciences, INC. | $400.80 | 2021-2025 | Veklury |
| Abbvie INC. | $330.10 | 2021-2025 | Dalvance |
| Melinta Therapeutics, LLC | $166.24 | 2020-2025 | Orbactiv, Kimyrsa, Rezzayo |
| Astellas Pharma US INC | $99.29 | 2019-2024 | |
| Pfizer INC. | $97.43 | 2022-2025 | |
| Napo Pharmaceuticals INC | $95.51 | 2025 | Mytesi |
| Shionogi INC | $65.95 | 2021-2025 | Fetroja |
| La Jolla Pharmaceutical Company | $64.97 | 2021-2025 | Zevtera |
| Mayne Pharma Commercial LLC | $38.91 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.48 | 2024 | Cuvitru |
| Grifols USA, LLC | $26.36 | 2024 | Xembify |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $26.26 | 2025 | Vibativ |
| Ferring Pharmaceuticals INC. | $25.19 | 2024 | Rebyota |
| Surgenex LLC | $24.28 | 2025 | Renograft, Ardeograft, Surmatrix |
| Organogenesis INC. | $17.48 | 2025 | Puraply Wound Matrix |
| Allergan, INC. | $17.36 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.32 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $14.98 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vidhya Sabapathy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.